Global Information
회사소개 | 문의

세계의 오토인젝터 시장 예측(-2023년) : 류마티스 관절염, 다발성 경화증, 당뇨병, 아나필락시스

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023

리서치사 MarketsandMarkets
발행일 2018년 08월 상품 코드 671105
페이지 정보 영문 134 Pages
가격
US $ 5,650 ₩ 6,472,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,650 ₩ 7,617,500 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,150 ₩ 9,335,800 PDF by E-mail (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없지만, 동일 국가의 동일 사업장에 한정되며 해외지점 등은 포함되지 않습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,000 ₩ 11,455,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 오토인젝터 시장 예측(-2023년) : 류마티스 관절염, 다발성 경화증, 당뇨병, 아나필락시스 Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023
발행일: 2018년 08월 페이지 정보 : 영문 134 Pages

한글목차

세계의 오토인젝터 시장은 2018년의 289억 1,000만 달러에서 2023년까지 853억 1,000만 달러에 달할 것으로 예측되며, 이 기간의 CAGR(연평균 성장률)은 24.2%가 전망됩니다. 표적치료의 침투, 아나필락시스 발증률의 증가, 규제 승인 수의 증가 및 오토인젝터 장비의 기술 진보는 오토인젝터 시장의 성장을 촉진할 것으로 예측됩니다. 그러나 경구 당뇨병약 및 에피네프린 나잘 스프레이 등 약물전달 대체 경로에 대한 선호도는 이 시장의 성장을 다소 억제할 것으로 예측됩니다.

세계의 오토인젝터 시장에 대해 조사했으며, 시장의 기본 구조 및 각 부문·지역별 상세 동향과 예측, 시장 성장의 주요 촉진·저해요인, 시장의 기회·과제, 시장 발전의 방향성, 경쟁 분석, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 서론

제2장 조사 방법

제3장 개요

제4장 프리미엄 인사이트

  • 오토인젝터 시장의 개요
  • 오토인젝터 시장 : 종류별
  • 오토인젝터 시장의 지역 분석 : 치료별
  • 오토인젝터 시장 : 최종사용자별
  • 지역 개요 : 오토인젝터 시장

제5장 시장 개요

  • 서론
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 저해요인
    • 시장 기회
    • 시장이 해결해야 할 과제

제6장 오토인젝터 시장 : 치료별

  • 서론
  • 류마티스 관절염
  • 다발성 경화증
  • 당뇨병
  • 아나필락시스
  • 기타

제7장 오토인젝터 시장 : 종류별

  • 서론
    • 일회용 오토인젝터
    • 재사용 오토인젝터

제8장 오토인젝터 시장 : 최종사용자별

  • 서론
  • 홈케어
  • 병원 & 진료소

제9장 오토인젝터 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양(APAC)
  • 기타(ROW)

제10장 경쟁 환경

  • 개요
  • 시장 점유율 분석
  • OEM 기업의 시장 순위
  • 시장 점유율 분석 : 치료 영역별
  • 경쟁 구도

제11장 기업 개요

  • ABBVIE
  • MYLAN
  • ELI LILLY
  • YPSOMED
  • AMGEN
  • BECTON, DICKINSON AND COMPANY
  • OWEN MUMFORD
  • CONSORT MEDICAL
  • HASELMEIER
  • SHL GROUP(SCANDINAVIAN HEALTH LIMITED)
  • JOHNSON & JOHNSON(J&J)
  • TEVA
  • ANTARES PHARMA

제12장 부록

KSA 18.08.09

LIST OF TABLES

  • TABLE 1: RECENT APPROVALS OF AUTOINJECTOR DEVICES ACROSS THE GLOBE
  • TABLE 2: PATENT EXPIRY OF KEY BIOLOGICS
  • TABLE 3: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 4: AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 5: AUTOINJECTORS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 6: AUTOINJECTORS MARKET FOR DIABETES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 7: AUTOINJECTORS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 8: AUTOINJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 9: COMPARISON OF DISPOSABLE & REUSABLE AUTOINJECTORS
  • TABLE 10: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 11: DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 12: REUSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 13: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 14: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 15: AUTOINJECTORS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 16: AUTOINJECTORS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 17: NORTH AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 18: NORTH AMERICA: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 19: NORTH AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 20: NORTH AMERICA: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 21: AUTOINJECTORS APPROVED BY THE FDA, 2015-2018
  • TABLE 22: US: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 23: US: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 24: US: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 25: CANADA: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 26: CANADA: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 27: CANADA: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 28: PRODUCT APPROVALS IN EUROPE, 2015-2018
  • TABLE 29: EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 30: EUROPE: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 31: EUROPE: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 32: EUROPE: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 33: GERMANY: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 34: GERMANY: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 35: GERMANY: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 36: UK: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 37: UK: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 38: UK: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 39: FRANCE: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 40: FRANCE: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 41: FRANCE: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 42: ROE: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 43: ROE: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 44: ROE: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 45: ASIA PACIFIC: AUTOINJECTORS MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 46: ASIA PACIFIC: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 47: ASIA PACIFIC: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 48: ASIA PACIFIC: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 49: JAPAN: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 50: JAPAN: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 51: JAPAN: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 52: CHINA: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 53: CHINA: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 54: CHINA: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 55: INDIA: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 56: INDIA: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 57: INDIA: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 58: ROAPAC: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 59: ROAPAC: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 60: ROAPAC: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 61: ROW: AUTOINJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 62: ROW: AUTOINJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 63: ROW: AUTOINJECTORS MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 64: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 65: EXPANSIONS
  • TABLE 66: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

LIST OF FIGURES

  • FIGURE 1: AUTOINJECTORS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: RESEARCH DESIGN
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: RHEUMATOID ARTHRITIS THERAPY SEGMENT TO DOMINATE THE AUTOINJECTORS MARKET IN 2018
  • FIGURE 8: DISPOSABLE AUTOINJECTORS TO ACCOUNT FOR THE LARGEST SHARE OF THE AUTOINJECTORS MARKET IN 2018
  • FIGURE 9: HOME CARE SETTINGS TO DOMINATE THE AUTOINJECTORS MARKET DURING THE FORECAST PERIOD
  • FIGURE 10: NORTH AMERICA TO WITNESS THE HIGHEST MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 11: GROWING PREVALENCE OF TARGETED THERAPIES AND INCREASING NUMBER OF REGULATORY APPROVALS ARE DRIVING MARKET GROWTH
  • FIGURE 12: DISPOSABLE AUTOINJECTORS TO DOMINATE THE MARKET IN 2018
  • FIGURE 13: RHEUMATOID ARTHRITIS THERAPY SEGMENT TO COMMAND THE LARGEST SHARE OF THE AUTOINJECTORS MARKET IN 2018
  • FIGURE 14: HOME CARE SETTINGS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018
  • FIGURE 15: NORTH AMERICA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 16: AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 17: AUTOINJECTORS MARKET, BY THERAPY, 2018 VS. 2023 (USD BILLION)
  • FIGURE 18: AUTOINJECTORS MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 19: AUTOINJECTORS MARKET, BY END USER, 2018 VS. 2023 (USD BILLION)
  • FIGURE 20: NORTH AMERICA TO COMMAND THE LARGEST MARKET SHARE IN 2018
  • FIGURE 21: NORTH AMERICA: AUTOINJECTORS MARKET SNAPSHOT
  • FIGURE 22: EUROPE: AUTOINJECTORS MARKET SNAPSHOT
  • FIGURE 23: ASIA PACIFIC: AUTOINJECTORS MARKET SNAPSHOT
  • FIGURE 24: ROW: AUTOINJECTORS MARKET SNAPSHOT
  • FIGURE 25: MARKET RANKING OF OEM COMPANIES
  • FIGURE 26: STRATEGIES ADOPTED BY MARKET PLAYERS (2014-2018)
  • FIGURE 27: ABBVIE: COMPANY SNAPSHOT (2017)
  • FIGURE 28: MYLAN: COMPANY SNAPSHOT (2017)
  • FIGURE 29: ELI LILLY: COMPANY SNAPSHOT (2017)
  • FIGURE 30: YPSOMED: COMPANY SNAPSHOT (2017)
  • FIGURE 31: AMGEN: COMPANY SNAPSHOT (2017)
  • FIGURE 32: BD: COMPANY SNAPSHOT (2017) 112  
  • FIGURE 33: CONSORT MEDICAL: COMPANY SNAPSHOT (2017)
  • FIGURE 34: JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017)
  • FIGURE 35: TEVA: COMPANY SNAPSHOT (2017)
  • FIGURE 36: ANTARES PHARMA: COMPANY SNAPSHOT (2017)

영문목차

"The autoinjectors market is projected to grow at a CAGR of 24.2% during the forecast period."

The global autoinjectors market is expected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period. Growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, and technological advancements in autoinjector devices are expected to drive the growth of the autoinjectors market. However, the preference for alternative routes of drug delivery such as oral diabetic agents and epinephrine nasal sprays is expected to restrain the growth of this market to a certain extent.

"By therapy, the rheumatoid arthritis segment is expected to grow at the highest CAGR during the study period."

Based on therapy, the global autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. The rheumatoid arthritis segment is expected to grow at the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the high prevalence of rheumatoid arthritis across the globe.

"By type, the disposable autoinjectors segment is expected to grow at the highest rate during the forecast period (2018-2023)."

Based on type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the benefits these autoinjectors offer, such as portability, ease of use, and a lower possibility of infection.

"The North American autoinjectors market is expected to grow at the highest CAGR during the forecast period."

North America is expected to witness the highest growth from 2018 to 2023. This can be attributed to the rising prevalence of anaphylaxis, autoimmune diseases, and chronic diseases in the US and Canada; favorable reimbursement scenario; and increasing number of awareness programs in the region.

Break of primary participants was as mentioned below:

The key players in the global autoinjectors market are: Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US), Merck (US), Ypsomed (Switzerland), AstraZeneca (UK), J&J (US), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), Bayer (Germany), and Haselmeier (Switzerland).

Research Coverage:

The report analyzes the autoinjectors market and aims at estimating the market size and future growth potential of this market based on various segments such as therapy, type, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one or any combination of the below mentioned five strategies.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the autoinjectors market. The report analyzes the market based on therapy, type, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the autoinjectors market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various autoinjectors across regions
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the autoinjectors market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. YEARS CONSIDERED FOR THE STUDY
    • 1.3.2. MARKETS COVERED
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. key data from primary sources
      • 2.2.2.2. Key industry insights
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. AUTOINJECTORS MARKET OVERVIEW
  • 4.2. AUTOINJECTORS MARKET, BY TYPE, 2018 VS. 2023
  • 4.3. GEOGRAPHIC ANALYSIS: AUTOINJECTORS MARKET, BY THERAPY
  • 4.4. AUTOINJECTORS MARKET, BY END USER, 2018 VS. 2023
  • 4.5. GEOGRAPHIC SNAPSHOT: AUTOINJECTORS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Growing prevalence of targeted therapies
      • 5.2.1.2. Rising incidence of anaphylaxis
      • 5.2.1.3. Increasing number of regulatory approvals
      • 5.2.1.4. Availability of generic versions of autoinjectors
      • 5.2.1.5. Favorable reimbursements and government support
      • 5.2.1.6. Technological advancements and design development
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Preference for alternative drug delivery modes
        • 5.2.2.1.1. Oral diabetic agents and oral insulin
        • 5.2.2.1.2. Epinephrine nasal sprays
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Patent expiry of biologics to drive the demand for biosimilars
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Development of autoinjectors for multiple drug viscosities
      • 5.2.4.2. Lack of proper training for using autoinjectors

6. AUTOINJECTORS MARKET, BY THERAPY

  • 6.1. INTRODUCTION
  • 6.2. RHEUMATOID ARTHRITIS
  • 6.3. MULTIPLE SCLEROSIS
  • 6.4. DIABETES
  • 6.5. ANAPHYLAXIS
  • 6.6. OTHER THERAPIES

7. AUTOINJECTORS MARKET, BY TYPE

  • 7.1. INTRODUCTION
    • 7.1.1. DISPOSABLE AUTOINJECTORS
    • 7.1.2. REUSABLE AUTOINJECTORS

8. AUTOINJECTORS MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. HOME CARE SETTINGS
  • 8.3. HOSPITALS & CLINICS

9. AUTOINJECTORS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. US
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
    • 9.3.2. UK
    • 9.3.3. FRANCE
    • 9.3.4. REST OF EUROPE
  • 9.4. ASIA PACIFIC
    • 9.4.1. JAPAN
    • 9.4.2. CHINA
    • 9.4.3. INDIA
    • 9.4.4. ROAPAC
  • 9.5. REST OF THE WORLD

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
  • 10.3. MARKET RANKING OF OEM COMPANIES
  • 10.4. MARKET SHARE ANALYSIS, BY THERAPEUTIC AREA
    • 10.4.1. RHEUMATOID ARTHRITIS
    • 10.4.2. MULTIPLE SCLEROSIS
    • 10.4.3. DIABETES
    • 10.4.4. ANAPHYLAXIS
  • 10.5. COMPETITIVE SCENARIO
    • 10.5.1. PRODUCT LAUNCHES AND APPROVALS
    • 10.5.2. EXPANSIONS
    • 10.5.3. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

11. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, MnM View)*

  • 11.1. ABBVIE
  • 11.2. MYLAN
  • 11.3. ELI LILLY
  • 11.4. YPSOMED
  • 11.5. AMGEN
  • 11.6. BECTON, DICKINSON AND COMPANY
  • 11.7. OWEN MUMFORD
  • 11.8. CONSORT MEDICAL
  • 11.9. HASELMEIER
  • 11.10. SHL GROUP (SCANDINAVIAN HEALTH LIMITED)
  • 11.11. JOHNSON & JOHNSON (J&J)
  • 11.12. TEVA
  • 11.13. ANTARES PHARMA

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. DISCUSSION GUIDE
  • 12.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3. AVAILABLE CUSTOMIZATIONS
  • 12.4. RELATED REPORTS
  • 12.5. AUTHOR DETAILS
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research